文献速递眼底病与葡萄膜炎

CATT 五年结果:黄斑形态与视力关联持续存在

Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials.
PubMed 文献 · Ophthalmology · 2018-09-03

CATT 队列研究评估年龄相关性黄斑变性伴脉络膜新生血管眼在第五年时黄斑形态特征与视力的关联,523 只眼完成影像与视力分析。SHRM、视网膜变薄、CNV 病灶面积较大、黄斑中心病理及 IRF 独立关联更差视力;第 2 至 5 年间 8 项病理特征新发或加重独立关联视力下降。

要点

  • 第五年时 60% 眼有 IRF、38% 有 SRF、36% 有 sub-RPE 液、66% 有 SHRM。
  • SHRM、视网膜变薄、CNV 面积大、黄斑中心病理及 IRF 独立关联更差视力。
  • 第 2 至 5 年新发黄斑瘢痕、CNV、IRF、SHRM、视网膜变薄及 GA 加重关联视力下降。

核心结论

  • 第一年识别的视力与形态特征关联在第五年维持或增强。
  • 新发黄斑瘢痕、CNV、IRF、SHRM、视网膜变薄、黄斑 GA 发生或加重及病灶增大是第 2 至 5 年视力下降的重要贡献因素。
  • 仍显著需要开发针对这些不良病理特征的治疗。

研究设计与样本

  • 随机临床试验内的队列研究,对象为 CATT 参与者。
  • 入组眼为 AMD 相关 CNV 且视力在 20/25 至 20/320 之间。
  • 前 2 年随机分配雷珠单抗或贝伐珠单抗及 3 种给药方案,此后由眼科医生决定治疗。
  • 5 年时 914 名存活参与者中 523 眼(57%)有视力和图像分级数据。

主要发现

  • 5 年时 60% 眼有 IRF,38% 有 SRF,36% 有 sub-RPE 液,66% 有 SHRM。
  • 黄斑中心厚度均值(标准差):视网膜 148 μm(99),SRF 5 μm(21),视网膜下组织复合体 125 μm(107),SHRM 11 μm(33),RPE+RPE 抬高 103 μm(95)。
  • SHRM、视网膜较薄、CNV 病灶面积较大、黄斑中心病理(均 P < 0.001)及 IRF(P < 0.05)独立关联更差视力。
  • 校正后平均视力字母数:黄斑中心无病理 62;CNV、液或出血 61;非地理萎缩(GA)65;非纤维化瘢痕 64;GA 53;纤维化瘢痕 56。
  • 第 2 至 5 年间 8 项病理特征(黄斑 GA、黄斑瘢痕、黄斑 CNV、SHRM、黄斑 IRF、视网膜变薄、CNV 病灶面积、GA 面积)新发或加重独立关联第 2 至 5 年更大视力丢失及基线至第 5 年视力丢失。

关键数值与推荐

  • SHRM、视网膜较薄、CNV 病灶面积较大、黄斑中心病理(均 P < 0.001)及 IRF(P < 0.05)独立关联更差视力。
  • 校正后平均视力字母数:无病理 62;CNV、液或出血 61;非 GA 65;非纤维化瘢痕 64;GA 53;纤维化瘢痕 56。
  • 5 年时 IRF 60%、SRF 38%、sub-RPE 液 36%、SHRM 66%。

临床怎么用

  • 长期随访中应关注 SHRM、IRF、视网膜变薄、CNV 面积增大及黄斑 GA 等形态特征。
  • 第 2 至 5 年新发或加重的黄斑瘢痕、CNV、IRF、SHRM、视网膜变薄及 GA 与视力下降相关。
  • 现有治疗下仍需针对上述不良病理特征开发新疗法。

局限性

  • 5 年时仅 57% 存活参与者(523/914)有视力和图像分级数据。
  • 前 2 年后治疗由眼科医生决定,非随机比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate associations of morphologic features with 5-year visual acuity (VA) in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT). DESIGN: Cohort study within a randomized clinical trial. PARTICIPANTS: Participants in CATT. METHODS: Eyes with age-related macular degeneration-associated choroidal neovascularization (CNV) and VA between 20/25 and 20/320 were eligible. Treatment was assigned randomly to ranibizumab or bevacizumab and to 3 dosing regimens for 2 years and was at the ophthalmologists' discretion thereafter. MAIN OUTCOME MEASURES: Visual acuity, thickness and morphologic features on OCT, and lesion size and foveal composition on fundus photography (FP) and fluorescein angiography (FA). RESULTS: Visual acuity and image gradings were available for 523 of 914 participants (57%) alive at 5 years. At 5 years, 60% of eyes had intraretinal fluid (IRF), 38% had subretinal fluid (SRF), 36% had subretinal pigment epithelium (RPE) fluid, and 66% had subretinal hyper-reflective material (SHRM). Mean (standard deviation) foveal center thickness was 148 μm (99) for retina, 5 μm (21) for SRF, 125 μm (107) for subretinal tissue complex, 11 μm (33) for SHRM, and 103 μm (95) for RPE + RPE elevation. The SHRM, thinner retina, greater CNV lesion area, and foveal center pathology (all P < 0.001) and IRF (P < 0.05) were independently associated with worse VA. Adjusted mean VA letters were 62 for no pathology in the foveal center; 61 for CNV, fluid, or hemorrhage; 65 for non-geographic atrophy (GA); 64 for nonfibrotic scar; 53 for GA; and 56 for fibrotic scar. Incidence or worsening of 8 pathologic features (foveal GA, foveal scar, foveal CNV, SHRM, foveal IRF, retinal thinning, CNV lesion area, and GA area) between years 2 and 5 was independently associated with greater loss of VA from years 2 to 5 and VA loss from baseline to year 5. CONCLUSIONS: Associations between VA and morphologic features previously identified through year 1 were maintained or strengthened at year 5. New foveal scar, CNV, intraretinal fluid, SHRM and retinal thinning, development or worsening of foveal GA, and increased lesion size are important contributors to the VA decline from years 2 to 5. A significant need to develop therapies to address these adverse pathologic features remains.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Jaffe GJ, Ying GS, Toth CA, et al. Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials. Ophthalmology. 2018. PMID: 30189282. doi:10.1016/j.ophtha.2018.08.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。